Matches in SemOpenAlex for { <https://semopenalex.org/work/W4210363402> ?p ?o ?g. }
- W4210363402 endingPage "1322" @default.
- W4210363402 startingPage "1312" @default.
- W4210363402 abstract "Neoadjuvant gemcitabine and cisplatin (GC) followed by radical cystectomy (RC) is standard for patients with muscle-invasive bladder cancer (MIBC). On the basis of the activity of atezolizumab (A) in metastatic BC, we tested neoadjuvant GC plus A for MIBC.Eligible patients with MIBC (cT2-T4aN0M0) received a dose of A, followed 2 weeks later by GC plus A every 21 days for four cycles followed 3 weeks later by a dose of A before RC. The primary end point was non-muscle-invasive downstaging to < pT2N0.Of 44 enrolled patients, 39 were evaluable. The primary end point was met, with 27 of 39 patients (69%) < pT2N0, including 16 (41%) pT0N0. No patient with < pT2N0 relapsed and four (11%) with ≥ pT2N0 relapsed with a median follow-up of 16.5 months (range: 7.0-33.7 months). One patient refused RC and two developed metastatic disease before RC; all were considered nonresponders. The most common grade 3-4 adverse event (AE) was neutropenia (n = 16; 36%). Grade 3 immune-related AEs occurred in five (11%) patients with two (5%) requiring systemic steroids. The median time from last dose of chemotherapy to surgery was 7.8 weeks (range: 5.1-17 weeks), and no patient failed to undergo RC because of AEs. Four of 39 (10%) patients had programmed death-ligand 1 (PD-L1)-positive tumors and were all < pT2N0. Of the patients with PD-L1 low or negative tumors, 23 of 34 (68%) achieved < pT2N0 and 11 of 34 (32%) were ≥ pT2N0 (P = .3 for association between PD-L1 and < pT2N0).Neoadjuvant GC plus A is a promising regimen for MIBC and warrants further study. Patients with < pT2N0 experienced improved relapse-free survival. The PD-L1 positivity rate was low compared with published data, which limits conclusions regarding PD-L1 as a predictive biomarker." @default.
- W4210363402 created "2022-02-08" @default.
- W4210363402 creator A5018855400 @default.
- W4210363402 creator A5019331033 @default.
- W4210363402 creator A5019370931 @default.
- W4210363402 creator A5019379068 @default.
- W4210363402 creator A5020465149 @default.
- W4210363402 creator A5022477189 @default.
- W4210363402 creator A5026511535 @default.
- W4210363402 creator A5026975414 @default.
- W4210363402 creator A5028996773 @default.
- W4210363402 creator A5030718677 @default.
- W4210363402 creator A5031667361 @default.
- W4210363402 creator A5032928016 @default.
- W4210363402 creator A5034278848 @default.
- W4210363402 creator A5034796364 @default.
- W4210363402 creator A5035462260 @default.
- W4210363402 creator A5036106560 @default.
- W4210363402 creator A5043587463 @default.
- W4210363402 creator A5044834942 @default.
- W4210363402 creator A5044999723 @default.
- W4210363402 creator A5045117637 @default.
- W4210363402 creator A5045218905 @default.
- W4210363402 creator A5046867621 @default.
- W4210363402 creator A5047305656 @default.
- W4210363402 creator A5047583027 @default.
- W4210363402 creator A5048541532 @default.
- W4210363402 creator A5048724240 @default.
- W4210363402 creator A5050435057 @default.
- W4210363402 creator A5053307625 @default.
- W4210363402 creator A5054246379 @default.
- W4210363402 creator A5061950952 @default.
- W4210363402 creator A5062108383 @default.
- W4210363402 creator A5064292088 @default.
- W4210363402 creator A5064884168 @default.
- W4210363402 creator A5067271492 @default.
- W4210363402 creator A5067522153 @default.
- W4210363402 creator A5071050839 @default.
- W4210363402 creator A5071418777 @default.
- W4210363402 creator A5078098363 @default.
- W4210363402 creator A5078516843 @default.
- W4210363402 date "2022-04-20" @default.
- W4210363402 modified "2023-10-14" @default.
- W4210363402 title "Neoadjuvant Atezolizumab With Gemcitabine and Cisplatin in Patients With Muscle-Invasive Bladder Cancer: A Multicenter, Single-Arm, Phase II Trial" @default.
- W4210363402 cites W1513738801 @default.
- W4210363402 cites W1845099892 @default.
- W4210363402 cites W1975918912 @default.
- W4210363402 cites W1985213644 @default.
- W4210363402 cites W1988160404 @default.
- W4210363402 cites W2015058156 @default.
- W4210363402 cites W2047902191 @default.
- W4210363402 cites W2056893124 @default.
- W4210363402 cites W2071069178 @default.
- W4210363402 cites W2073175347 @default.
- W4210363402 cites W2073804272 @default.
- W4210363402 cites W2075894019 @default.
- W4210363402 cites W2087179076 @default.
- W4210363402 cites W2101562875 @default.
- W4210363402 cites W2103561213 @default.
- W4210363402 cites W2103725052 @default.
- W4210363402 cites W2111415894 @default.
- W4210363402 cites W2113156769 @default.
- W4210363402 cites W2114788594 @default.
- W4210363402 cites W2133862671 @default.
- W4210363402 cites W2147415463 @default.
- W4210363402 cites W2160107406 @default.
- W4210363402 cites W2164791945 @default.
- W4210363402 cites W2166453367 @default.
- W4210363402 cites W2210089256 @default.
- W4210363402 cites W2289712604 @default.
- W4210363402 cites W2398135534 @default.
- W4210363402 cites W2414977199 @default.
- W4210363402 cites W2582671354 @default.
- W4210363402 cites W2588916311 @default.
- W4210363402 cites W2597872842 @default.
- W4210363402 cites W2619249519 @default.
- W4210363402 cites W2771737095 @default.
- W4210363402 cites W2777192533 @default.
- W4210363402 cites W2802899563 @default.
- W4210363402 cites W2805354595 @default.
- W4210363402 cites W2893960509 @default.
- W4210363402 cites W2897422388 @default.
- W4210363402 cites W2897581535 @default.
- W4210363402 cites W2966500633 @default.
- W4210363402 cites W2987436342 @default.
- W4210363402 cites W2995899912 @default.
- W4210363402 cites W3007839305 @default.
- W4210363402 cites W3008190565 @default.
- W4210363402 cites W3009112563 @default.
- W4210363402 cites W3021010739 @default.
- W4210363402 cites W3024551702 @default.
- W4210363402 cites W3032403184 @default.
- W4210363402 cites W3081622691 @default.
- W4210363402 cites W3087883993 @default.
- W4210363402 cites W3088168604 @default.
- W4210363402 cites W3089266118 @default.
- W4210363402 cites W3127912627 @default.
- W4210363402 cites W3134370939 @default.